[8-K] AbCellera Biologics Inc. Reports Material Event

Rhea-AI Filing Summary

AbCellera Biologics Inc. disclosed that on December 18, 2025 it issued a press release announcing a settlement and patent license agreement with Bruker Corporation. This agreement resolves the patent litigation between the two companies on a global basis, ending the dispute over intellectual property rights worldwide. The press release detailing the settlement and license terms is provided as Exhibit 99.1 to this report, and the information is furnished under Regulation FD rather than filed for liability purposes.

Insights

Equity & IP risk analyst

AbCellera and Bruker have globally settled their patent litigation via a license deal.

AbCellera Biologics Inc. reports that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving their patent litigation globally. This removes an ongoing legal overhang related to intellectual property disputes between the two companies.

The report characterizes this as a global resolution, which suggests the settlement and license cover multiple jurisdictions where the litigation had been active. Specific financial terms or duration of the license are not disclosed in this excerpt, so the economic impact cannot be assessed here.

The key point for investors is that an active patent dispute has been resolved through a licensing arrangement, potentially reducing legal uncertainty. More detail on the settlement structure, scope of licensed technology, and any payments would be found in the press release referenced as Exhibit 99.1 dated December 18, 2025.

0001703057falseVancouverBC00017030572025-12-182025-12-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 18, 2025

__________________________________________

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

British Columbia			001-39781			Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

150 W 4th Avenue Vancouver, BC			V5Y 1G6
(Address of registrant’s principal executive office)			(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common shares			ABCL			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 7.01    Regulation FD Disclosure

On December 18, 2025, AbCellera Biologics Inc. issued a press release announcing it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d)Exhibits

Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on December 18, 2025.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 18, 2025			ABCELLERA BIOLOGICS INC.
			By:			/s/ Carl L. G. Hansen
						Carl L. G. Hansen, Ph.D.
						Chief Executive Officer and Director (Principal Executive Officer)

FAQ

What did AbCellera Biologics Inc. (ABCL) announce on December 18, 2025?

AbCellera Biologics Inc. announced that it entered into a settlement and patent license agreement with Bruker Corporation, resolving patent litigation between the two companies globally.

Which companies are involved in the patent settlement with AbCellera Biologics Inc. (ABCL)?

The settlement and patent license agreement is between AbCellera Biologics Inc. and Bruker Corporation, and it resolves the patent litigation between these two companies globally.

Does the agreement between AbCellera (ABCL) and Bruker resolve litigation worldwide?

Yes. The company states that the settlement and patent license agreement with Bruker Corporation resolves the patent litigation between the two companies globally.

Where can investors find more details on AbCellera’s settlement with Bruker?

More details are contained in the press release issued on December 18, 2025, which is included as Exhibit 99.1 to this report.

Is the information about AbCellera’s settlement with Bruker considered filed or furnished?

The information provided under Item 7.01, including Exhibit 99.1, is expressly described as being furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

What exhibits accompany AbCellera Biologics Inc.’s report about the Bruker settlement?

The report includes Exhibit 99.1, the press release dated December 18, 2025, and Exhibit 104, the cover page interactive data file embedded as Inline XBRL.